Profile data is unavailable for this security.
About the company
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
- Revenue in HKD (TTM)6.81m
- Net income in HKD-746.44m
- Incorporated--
- Employees477.00
- LocationCARsgen Therapeutics Holdings LtdBuilding 12No.388 Yindu Road, Xuhui DistrictSHANGHAI KY1-1205ChinaCHN
- Websitehttps://www.carsgen.com/
More ▼